Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Creating an informational home pharmacy |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
|
Survey
This month we would like to know...
In your practice setting, has the process for Risk Evaluation and Mitigation Strategies (REMS) implementation been automated?
• Yes, we are using an automated system.
• No, we are not yet using an automated system.
• No, but we plan to use an automated system in the next 6 months.
• No, but we plan to use an automated system in the next 12 months.
|
|
|
For the fourth consecutive year, diabetes therapy topped the list of contributors to drug use trends in therapeutic categories, contributing 16.7% to overall growth in drug spending in 2010 due to an increasing number of patients, according to the recently released 2011 Medco Drug Trend Report. Read full article. |
 |
|
|
 |
A discussion generated by
Drug Topics’ readers, editorial staff, and advisory board
Oluwole Williams lives in Glenside, Pa., where he works as a relief pharmacist. |
The peculiar experiences of a floater pharmacist
Read full article.
|
|
FDA approved telaprevir (Incivek, Vertex) tablets to treat certain adults with chronic hepatitis C infection. Read full article.
|
|
New competency reports for pharmacists and other healthcare professionals aim to set forth strategies that will help providers work together better. Read full article.
|
|
Denosumab (Xgeva, Amgen) significantly increased bone metastasis-free survival for more than 4 months in men with castrate-resistant metastatic prostate cancer that had not yet spread to bone, according to results of a landmark study of Xgeva, presented at a late-breaking plenary session at the American Urological Association's 2011 annual meeting in Washington, DC. Read full article.
|
There is no safe therapeutic window of time for using NSAIDs in patients with prior myocardial infarction. Even short-term treatment with most NSAIDs appears associated with increased risk of death and recurrent MI, reported a study published in Circulation. Read full article. |
|
Proton pump inhibitors are associated with a 29% increased risk of fracture, including a 31% increased risk of hip fracture and a 54% increased risk of vertebral fracture, according to a study published in the May/June 2011 issue of Annals of Family Medicine. Read full article. |
|
In a closely watched vote, pharmacists at Kaiser Permanente Southern California voted down a tentative contract negotiated by the Guild for Professional Pharmacists. Read full article. |
|
Allergic rhinitis patients are likely to have sleep disturbances and are not likely to be satisfied with the nasal sprays on the market, according to the new Nasal Allergy Survey Assessing Limitations 2010 study. Read full article. |
 |
Meetings and Events
June 1-2, 2011 PQA Annual Meeting
Washington, DC
Contact:
Karen Peterson
9687 South Run Oaks Drive
Fairfax Station, VA 22039
Fax: 703-690-1756
[email protected]
June 2-3 PQA/URAC Medication Adherence Summit
Washington, DC
Contact:
Jackie Green
1220 L Street NW, Suite 400
Washington, DC 20005
703-927-1599
[email protected]
June 3-5 NCPA Diabetes Accreditation Standards-Practical Applications (DASPA)
Brooklyn, NY
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
July 22-25, 2011 NPhA Annual Convention
Atlanta
Contact:
107 Kilmayne Drive, Suite C
Cary, NC 27511
Phone: 404-262-3344
Fax: 404-262-8689
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
